Header Ads

πŸ“ˆπŸ“ˆ Bullish Penny Stocks $1-$10 for tomorrow 6.18.2019 πŸ’΅πŸ’΅ - #stockstowatch #pennystocks

What Is a Penny Stock: A penny stock refers to a small company's stock that typically trades for less than $5 per share. Although some penny stocks trade on large exchanges such as the New York Stock Exchange (NYSE), most penny stocks trade via over the counter (OTC) transactions. Transactions take place through the electronic OTC Bulletin Board (OTCBB) or through the privately-owned Pink Sheets. There is no trading floor for OTC transactions, and the quotations are also all done electronically.


Jonny Red's Penny Stock Trade Thoughts Below:

The below listed Penny Stock Tickers are all those that meet the criteria of the scanner.  These are tickers that need to be watched and analyzed at Market Open to see if they will continue their Northern Momentum. I have posted a few of the charts for my favorite ones.

All of these tickers close today with 3 consecutive Green closes. I typically always look for penny's stock plays that have 3 consecutive GREEN days, and at least 800k+ in volume.

Transparent Trader Bullish Penny Stocks $1-$10 Range: http://tos.mx/izmLDK

See all Bullish Tickers below, but My Top 3 Ticker Symbols are: PTN - CVE - TGTX

The northern movement for these 3 tickers has just started over the last couple trading sessions.  With all indicators pointing North with plenty of room to continue moving.


PTN - Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation, as well as melanocortin receptor 4 peptides and orally-active small molecules to treat genetic metabolic and obesity disorders. In addition, the company develops natriuretic peptide receptor systems comprising PL­3994, a natriuretic peptide receptor-A agonist, which has completed Phase I clinical study for the treatment of cardiovascular indications; and PL-5028, a dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.


CVE - Cenovus Energy Inc., together with its subsidiaries, develops, produces, and markets crude oil, natural gas liquids, and natural gas in Canada and the United States. The company's Oil Sands segment develops and produces bitumen in northeast Alberta. This segment's bitumen assets include Foster Creek, Christina Lake, and Narrows Lake, as well as other projects in the early stages of development, such as Telephone Lake. This segment also holds the Athabasca natural gas assets. Its Deep Basin segment holds assets primarily located in Elmworth-Wapiti, Kaybob-Edson, and Clearwater operating areas of British Columbia and Alberta, and include interests in natural gas processing facilities. The company's Refining and Marketing segment transports, sells, and refines crude oil into petroleum and chemical products. This segment owns a 50% interest ownership in two refineries in the United States; owns and operates a crude-by-rail terminal in Alberta; and markets third-party purchases and sales of product. Cenovus Energy Inc. is headquartered in Calgary, Canada.


TGTX - TG Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. The company has five B-cell targeted drug candidates in clinical development, with the lead two therapies, such as Ublituximab and Umbralisib in pivotal trials for CLL, NHL, and MS. Its Ublituximab is a novel anti-CD20 monoclonal antibody that has been glycoengineered for enhanced potency over first generation antibodies; and Umbralisib is an oral, once daily inhibitor of PI3K delta. The company also develops TG-1501, an anti-PD-L1 monoclonal antibody; TG-1701, an oral Bruton's Tyrosine Kinase; and TG-1801, an anti-CD47/CD19 bispecific antibody. TG Therapeutics, Inc. has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated; and Jubilant Biosys. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.


Sign up for Morning Brew/>


2 comments:

  1. Keep on doing what you guys are doing. Awesome work.

    ReplyDelete
  2. Want to know what Operation Lights Out is all about?

    Starting July 1st 2019 Transparent Traders will launch it's own alert service, for FREE!

    In time we know it will shut down the paid services, but that's the world we live in. Every time Transparent Traders has been attacked by a paid service in hopes of shutting us down, we always respond by offering the service they do but even better and for free.

    So here we are, come July 1st we will provide an alert service daily for those who signup through our link. The alerts will be messaged directly to you thorough Facebook messenger from our business page for easy access.

    Click for a Facebook message link to signup for free πŸ‘‡

    https://m.me/221358522149508?ref=fcd476018d88e03d67b86d418d8f9c1b2a22d47632d94c4ce0

    ReplyDelete